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Abstract
Background: The impact of COPD on patient’s quality of life is well established, but gender differences have
received little attention.
Methods: To describe factors associated with the health-related quality of life by gender: A cross-sectional
observational study (NCT01007734) was conducted in COPD patients followed by pulmonologists. The first patient
included had to be a woman. Data concerning the patient, COPD and their management were collected by the
physician. The patient had to fill in several questionnaires: Saint-George Hospital respiratory Questionnaire (SGRQ-C),
and motivation to quit smoking.
Results: Four hundred and thirty patients were included: mean age 63.9 ± 11.3 years; 57.4% were women. Women
were significantly younger than men (61.9 vs. 66.6) and their tobacco use was lower (37.1 vs. 40.4 PY).
Cardiovascular comorbidities were more frequent in men while osteoporosis, anxiety and depression were frequent
in women. The frequency of cough, sputum and the severity of dyspnea did not differ significantly between
genders. Lung function impairment was less severe in women than in men (mean FEV1 52% predicted normal
vs. 47. 8%). Anxiety score was higher (score 9.8 vs. 7.1) and quality of life (SGRQ-C) more impaired in women
(scores 50.6 vs. 45.4; p < 0.02) than in men. Moreover, in multivariate analysis, chronic sputum was associated with
higher SGRQ-C scores in women but not in men.
Conclusions: This study underlines that despite less airflow limitation, quality of life is more impacted by chronic
sputum in women than in men.
Keywords: COPD, Gender, Quality of life, Comorbidities, Chronic sputum
Background
According to WHO, chronic obstructive pulmonary dis-
ease (COPD) is now the fourth leading cause of death and
will become the third in 2020. Some studies have shown
that prevalence of COPD is increasing faster among
women than men with different geographic distributions.
In industrialized countries, COPD is usually associated
with the increase in active smoking in women [1,2], prob-
ably with an underestimation of the impact of working ex-
posure [3]. In the developing countries, the impact of
COPD seems to be more associated with exposure to bio-
mass in women [4].
Although COPD is the consequence of an interaction
between genetic predisposition and environmental ex-
posure, the influence of gender on the clinical expres-
sion of COPD has received limited attention. In general
practice, COPD in women who smoke is often under-
diagnosed [5,6]. Previous studies suggested that for the
same severity of the disease, women with COPD seem to
report more dyspnea and worse quality of life than men.
Quality of life is now a major component of the manage-
ment of the disease, and valid criteria are needed to assess
the efficacy of medication. Health status measurement is
becoming an important issue for the day-to-day manage-
ment of COPD patients in both primary and secondary
health care [7]. Studies report that a shorter survival is re-
lated to worse health status/HRQoL (Health-related Quality
of Life). Since health status is considered a major goal in
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managing the disease, physicians should focus on improv-
ing it. In addition, previous studies suggested that determi-
nants of quality of life related to respiratory status differ by
gender [8].
The first objective of our study (NCT01007734) was to
describe the main factors determining the quality of life re-
lated to respiratory status according to gender in patients
with moderate-to-severe COPD. The second objective was
to determine the characteristics of COPD by gender after
adjusting on age and active smoking.
Methods
This was a multicenter, descriptive, cross-sectional study
conducted in France from September 2009 to November
2010.
Physicians were recruited by telephone at random
among a database of French pulmonologists. Each pulmo-
nologist recruited at least three consecutive patients once
the first woman was included. Inclusion criteria were
outpatients more than 40 years old, with a spirometric
diagnosis of COPD according to GOLD guidelines with
post-bronchodilator FEV1/FVC under 0.70 and FEV1
under 80% predicted. Patients might have been followed
for COPD for at least three months. They provided writ-
ten informed consent and had to be able to complete the
Saint George Hospital Respiratory Questionnaire (SGRQ).
Exclusion criteria were as follows: recent exacerbation
within 6 weeks, current or history of asthma, patients with
long-term requirement of oxygen, non-invasive ventilation
or tracheotomy, or participating in another trial. The phys-
ician filled in a medical questionnaire with demographics,
comorbidities, COPD description, and COPD treatment
concerning the patient. Chronic cough was defined as
cough during 3 months and during two consecutive years,
which the admitted definition of chronic bronchitis, the
same definition was made for chronic sputum.
The BOD index was made with Body mass (<21 kg/m2),
Obstruction (FEV1) and level of Dyspnea (MRC) without
6 minutes walking test (not available). Patients com-
pleted the following self-administered questionnaires, the
(SGRQ-C), the Hospital Anxiety and Depression Scale
(HADS) and theMotivation to quit smoking (Q-MAT, ac-
tive smokers only).
The SGRQ is scaled from 0 (optimal health) to 100
(worst health) [9]. A total score and three sub-scores
(symptoms, activities, impacts) are calculated.
The French translated version of SGRQ had been stud-
ied by Bourbeau et al. [10] and showed higher test-retest
reliability (0.80).
The HADS is scaled [11] from 0 (no anxiety, no depres-
sion) to 21 (severe anxiety, or depression) for each sub-
scale, French version used since 1985 [12].
The Q-MAT [13] is scaled from 0 (lack of motivation)
to 20 (excellent motivation).
Statistical analysis
Descriptive statistics (qualitative and quantitative data)
were performed at baseline. We compared for clinical
components and quality of life, men and women, then and
after including significant factors, a multivariate model
was used to determine factors related to quality of life,
specifically for men and women, by stratifying by gender.
Correlations were determined using Spearman correlation.
Then, we correlated SGRQ total score with different vari-
ables using a multiple linear regression analysis using
backward Wald criteria (p < 0.20), with those variables that
significantly correlated with total SGRQ score. The criter-
ion for statistical significance was 0.05. The software pro-
gram used was SAS version 8.2.
The protocol was approved in France by the Comité
Consultatif sur le Traitement de l’Information en matière
de Recherche dans le domaine de la Santé (CCTIRS) and
the Commission National Computer and Freedoms (CNIL).
All patients were informed about the objectives of the
study, and agreed to participate and fill in the question-
naires. The study was conducted according to the recom-
mendations of the declaration of Helsinki for investigation
with human subjects.
Results
One hundred and forty-six physicians included 446 pa-
tients, among them 430 had data available for analysis.
Mean age of physicians was 51.9 years (SD 7.9) and 77.3%
of them were men. 60% of them were private practitioners
and 40% were employed by hospitals.
Among the patients, 57.4% of them were female and
42.6% male. Descriptive analysis (Table 1) showed that
women with COPD were younger, had lower BMI, and
were more un-employed and lived alone more than men.
Men were more frequently smokers or ex smokers than
women (97.8% versus 84. 6% p < 0.001) but frequency of
active smoking was higher in women, with a significant
difference in the amount of smoking. Cardiovascular
comorbidities, dyslipidemia, alcoholism and sleep apnea
syndrome were more frequent in men. By contrast,
osteoporosis, past anxiety and depression were more
frequent in women.
There was no difference between men and women re-
garding the frequency of cough and sputum and the se-
verity of dyspnea (Table 2). Women seemed to have
more exacerbations than men but the difference was not
statistically significant. Regarding the severity of COPD
according to the GOLD classification, there was a higher
proportion of stage 2 and less stage 4 in women com-
pared to men. Women used more short-acting ß2-ago-
nists, with no difference for other inhaled treatment for
COPD. There was a higher proportion of women with
anxiety as measured by the HAD questionnaire com-
pared to men.
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In active smokers, there was no difference in terms of
motivation to quit smoking between men and women
(Table 2). Women with COPD had significantly worse qual-
ity of life total scores (4 points of difference for clinical rele-
vance) compared with men, and a trend was observed for
each domain: symptoms, activities and impacts (Figure 1).
In the multivariate model to determine factors associ-
ated with quality of life, we only included variables with
less than 25% of data lacking, which decreased the size
of the sample.
Regarding factors associated with poor quality of life
(Table 3), the following factors were related in the global
population: severity of COPD (FEV1), severity of dyspnea,
chronic sputum, high number of treatments, previous lower
respiratory infections, and higher level of anxiety and de-
pression (HAD). Factors related to poor quality of life were
Table 1 Descriptive characteristics and co-morbities by gender
Men (n = 183) 42.6% Women (n = 247) 57.4% p n (M/W)
Mean age (years) 66.6 ± 10.8 61.9 ± 11.3 <0.001 175/242
% of subjects BMI <21 (Kg/m2) 14.9 29.5 0.002 102/147
Living alone at home (%) 17.6 36.1 <0.001 181/244
Unemployed 11.8 25.2 <0.001 170/238
Non-smoker/current smokers (%) 2.2/30.2 15.4/44.1 <0.001 182/247
Tobacco use (pack- years) 40.5 ±19 37 ±16 0.041 170/203
Comorbidities (%)
Arterial hypertension 41.4 32.9 NS 181/246
Ischemic heart disease 24.4 5.7 <0.001 180/245
Arteriopathy 12.2 3.7 0.001 181/245
Heart failure 8.4 2.9 0.011 178/245
Diabetes 11.5 6.5 NS 182/246
Dyslipidemia 26 16.7 < 0.02 181/246
Alcoholism 8.8 3.3 0.013 181/246
Sleep apnea syndrome 13.3 4.1 0.001 180/245
Osteoporosis 2.8 19.6 <0.001 178/240
Anxiety disorder 16.8 29.4 0.003 179/245
Depression disorder 4.6 19 <0.001 175/242
Table 2 Clinical description of COPD by gender
Men (n = 183) Women (n = 247) p n (M/W)
COPD symptoms (%) 42.6% 57.4%
Chronic cough 75.6 78.5
Chronic sputum 62 64.2 NS 182/245
Dyspnea MRC stage 0- 1–2 (%) 73.7 72.7 NS 179/242
Dyspnea MRC stage 3–4 (%) 26.3 27.3
COPD exacerbation (< 12 months) (%) 58.2 65.7 NS 182/245
FEV1 (% predicted) 46.2 ±14.4 52.1 ± 15.9 < 0.001 162/224
FEV1/FVC post BD 57.9 ± 13.6 58.9 ± 13.1 NS 170/231
GOLD stage 2 42.9% 54.6%
3 39.5% 37.4% 0.026 119/163
4 17.6% 8.0%
Short- acting ß2 -agonists 40 53.1 0.010 170/226
BOD index 2.9 ±1.6 2.6 ±1.6 NS 183/247
HAD anxiety sub-score (0–21) 7.1 ± 4.3 9.8 ± 4.3 < 0.001 131/177
HAD depression sub-score (0–21) 6.1 ± 4.4 6.6 ± 4.6 NS 128/177
Q- MAT score (0–20) 9.3 ±6 8.7 ±5.9 NS 46/93
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different in women compared with men. Chronic sputum
was significantly associated with poor quality of life in
women, whereas the number of treatments was associated
with it in men.
Discussion
This study was conducted to assess clinical differences
by gender in COPD patients and to determine factors
related to quality of life in an outpatient setting in
France.
Our study describes the clinical profile of COPD in
women and adds evidence for gender-related differences
adjusted on COPD severity. Women with COPD were
younger, had lower BMI, more unemployed and lived
more alone than men. Despite the lower severity of the
disease as assessed by GOLD staging, women with COPD
had a worse quality of life compared to men, and were
more impacted by chronic cough.
In the large Muvice Study [14], lower BMI was found in
women compared to men, suggesting that COPD may
affect nutritional status differently in women. Previously, a
high proportion of non-smokers and a lower proportion
of active smokers were found in women [14]. However,
this was not the case in our study, with a higher propor-
tion of active smokers in women compared to men. This
may be due to a change in smoking trends in France, al-
though a selection bias cannot be ruled out.
Skuliem et al. reported a greater proportion of women
living alone compared to men [15]. Social support could
be included in the management of these patients, in
order to improve education about treatment and adher-
ence to it. In turn, this could also help to reduce the
anxiety-depression that patients experience [16].
Cardiovascular comorbidities, dyslipidemia, alcoholism
and sleep apnea syndrome were more frequent in men. By
contrast, osteoporosis, past anxiety and depression were
more frequent in women. In the large EPIDEPOC study
[17], ischemic heart disease was more frequent in men
whereas hypertension, diabetes, anxiety and depression
were more frequent in women. Our finding could also re-
veal an underestimation of cardiovascular disease in
women in general practice. A high proportion of anxiety-
depression could influence the under-diagnosis of COPD
in women, as asthenia could mask dyspnea in women and
could be a negative factor of smoking cessation. The im-
pact of osteoporosis could also be important, because of
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Figure 1 Quality of life: SGRQ total score and subscores.
Table 3 Factors determining quality of life (SGRQ-C total score): multivariate analysis
Men Women Total
N = 75 N = 100 N = 175
COPD stage (GOLD) 4.37 [0.31; 8.43] 3.07 [−0.89; 7.02] 3.16 [0.37; 5.94]
p = 0.035 p = 0.127 p = 0.027
HAD depression 1.84 [1.12; 2.56] 1.89 [1.36; 2.41] 1.62 [1.09; 2.15]
Sub-score p < 0.001 p < 0.001 p < 0.001
MRC dyspnea score 17.07 [9.71; 24.44] 10.73 [4.80; 16.65] 12.37 [7.56; 17.19]
p < 0.001 p = 0.001 p < 0.001
Chronic sputum NS 8.33 [3.20; 13.45] p = 0.002 6.23 [2.22; 10.23] p = 0.003
Number of treatments 3.13 [1.26; 5.00] p = 0.001 NS 1.89 [0.50; 3.28] p = 0.008
β (95% IC); analysis done using factors with less than 25% of data lacking.
NS: non significant.
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the frequent prescription of oral corticosteroids to treat
exacerbation of COPD, which in turn could increase the
risk of osteoporosis and complications [18].
There was no difference between men and women re-
garding the frequency of cough, sputum and dyspnea.
However, with regard to the severity of the disease as
assessed by FEV1, COPD was less severe in women. In
other studies focusing on gender difference in patients
with COPD, this was previously observed [8,14,17] and it
was also the case in the Uplift study [19].
Finally, despite the lower severity of the disease as
assessed by GOLD staging, women with COPD had a
worse quality of life as measured by the SGRQ question-
naire compared with men, as reported previously [8,20]. In
addition, chronic sputum was significantly associated with
poor quality of life in women, whereas it was the number
of treatments which was associated with it in men. In a re-
cent meta-analysis by Tsiligianni et al. [7], health status was
evaluated by various questionnaires whose pertinence was
influenced by several factors. Dyspnea, anxiety and depres-
sion were more correlated with worse quality of life than
spirometric measurements, suggesting that quality of life
should be measured in addition to spirometry in the man-
agement of patients with COPD [7].
Our findings suggest that management of COPD should
take psychological distress and socioeconomic status into
account, particularly in women like those in our popula-
tion, who were more unemployed than men and lived
alone more. It is widely admitted in clinical practice that
women feel uneasy about expectorating or eliminating
sputum, or simply are unable to do so, but there is no
published evidence. Among our COPD patients followed
by specialists, there was the same proportion of patients
with sputum in women and in men, while this is a key
symptom of a lower quality of life mainly in women. Man-
agement with physiotherapy could improve quality of life
in such women.
Our study had some limitations. This could be due to the
design of the study, because the first patient included had
to be a woman so as to be sure that as many women as
men were included. Secondly, in the final model to deter-
mine factors associated with quality of life, we only in-
cluded variables with less than 25% of data lacking, which
decreased the size of the sample. A causal inference cannot
be drawn because of the cross sectional design of the study.
Our sample was made by patients with COPD referred to
pulmonologists, so we cannot generalize our results to the
population of COPD patients followed in general practice.
Conclusions
These findings show that although women experience less
airflow limitation, their quality of life in COPD seems
more impaired than that of men. Although FEV1 values
were higher in women compared to men, COPD had a
greater impact on them. It is too restrictive to assess COPD
severity only by testing lung function. Assessment of COPD
severity could take into account gender, co-morbidities and
quality of life in order to obtain a composite severity score.
Factors associated with quality of life differ according to
gender, with a specific impact of chronic sputum in women.
Management of women with COPD should incorporate
these specific characteristics, the impact of the disease and
gender-specific comorbidities in order to improve their
quality of life.
Abbreviation
COPD: Chronic obstructive pulmonary disease; SGRQ-C: Saint-George
Hospital respiratory Questionnaire; HADS: Hospital anxiety and depression
scale; QMAT: Motivation to quit smoking; WHO: World Health Organization;
BOD index: Body mass, Obstruction, dyspnea index.
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